found that the antisense oligonucleotide therapy (siRNAs) targeting exon 11 could rescue LMNA‐relate progeria and reduce prelamin A/progerin in favor of the alternative splicing of lamin C. Genome editing was used to correct LMNA‐relate progeria in two similar recent preclinical study,236, 237 suggesting that in other malignant LMNA missense variants, the HGPS gene editing model could be recapitulated. This evidence concerns the gene LMNA and progeroid syndrome.